Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Oncolytics Biotech (TSE:ONC)
TSX:ONC
RESEARCH TOOLSreports
Holding TSE:ONC?
Track your performance easily
ONC Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$1.15 - C$2.32
Previous CloseC$1.48
Volume41.14K
Average Volume (3M)109.76K
Market Cap
C$114.07M
Enterprise ValueC$90.34M
Total Cash (Recent Filing)C$24.85M
Total Debt (Recent Filing)C$1.12M
Price to Earnings (P/E)―
Beta0.21
Next Earnings
Mar 06, 2025EPS Estimate
-C$0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding76,986,033
10 Day Avg. Volume82,121
30 Day Avg. Volume109,757
Standard Deviation0.47
R-Squared0.02
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)5.83
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$6.09Price Target Upside334.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Oncolytics Biotech News
PremiumCompany Announcements
Oncolytics Biotech Reports Promising Cancer Treatment Results
PremiumCompany Announcements
Oncolytics Biotech Announces Q3 Results Conference
PremiumCompany Announcements
Oncolytics Biotech’s Cancer Drug Aims for Fast-Track ApprovalOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.05% Mutual Funds
0.61% Other Institutional Investors
99.34% Public Companies and
Individual Investors
ONC FAQ
What was Oncolytics Biotech’s price range in the past 12 months?
Oncolytics Biotech lowest stock price was C$1.15 and its highest was C$2.32 in the past 12 months.
What is Oncolytics Biotech’s market cap?
Currently, no data Available
When is Oncolytics Biotech’s upcoming earnings report date?
Oncolytics Biotech’s upcoming earnings report date is Mar 06, 2025 which is in 105 days.
How were Oncolytics Biotech’s earnings last quarter?
Oncolytics Biotech released its earnings results on Nov 12, 2024. The company reported -C$0.12 earnings per share for the quarter, missing the consensus estimate of -C$0.1 by -C$0.02.
Is Oncolytics Biotech overvalued?
According to Wall Street analysts Oncolytics Biotech’s price is currently Undervalued.
Does Oncolytics Biotech pay dividends?
Oncolytics Biotech does not currently pay dividends.
What is Oncolytics Biotech’s EPS estimate?
Oncolytics Biotech’s EPS estimate is -C$0.12.
How many shares outstanding does Oncolytics Biotech have?
Oncolytics Biotech has 77,074,090 shares outstanding.
What happened to Oncolytics Biotech’s price movement after its last earnings report?
Oncolytics Biotech reported an EPS of -C$0.12 in its last earnings report, missing expectations of -C$0.1. Following the earnings report the stock price went up 4.027%.
Which hedge fund is a major shareholder of Oncolytics Biotech?
Currently, no hedge funds are holding shares in TSE:ONC
---
Oncolytics Biotech Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$6.09 (334.77% Upside)
C$6.09 (334.77% Upside)
Blogger Sentiment
Bearish
TSE:ONC Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-29.33%
12-Months-Change
Fundamentals
Return on Equity
-144.22%
Trailing 12-Months
Asset Growth
-47.32%
Trailing 12-Months
Company Description
Oncolytics Biotech
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.
---
ONC Earnings Call
Q3 2024
0:00 / 0:00
---
ONC Stock 12 Month Forecast
Average Price Target
C$6.09
▲(334.77% Upside)
Technical Analysis
Oncolytics Biotech
―
Advaxis
―
Moleculin Biotech
―
Cyclacel Pharmaceuticals
―
TRACON Pharmaceuticals
―
Best Analysts Covering ONC
1 Year
1 Year Success Rate
7/14 ratings generated profit
1 Year Average Return
-8.56%
reiterated a buy rating 9 days ago
Copying John Newman's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -8.56% per trade.
---